Arca
Skip to content
Tools
Tools

Thalassemia

Drug research and approvals for thalassemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 63 studies of thalassemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 17 drug trials for it since 2013, FDA has 11 approved and 19 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 63
  • Trials authorized in Canada: 17
  • FDA orphan approvals: 11
  • EU medicines: 3

Recruiting now

Newest posted first, of 63 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 1

Phase 2 12 of 15

Phase 1 or earlier 5

How its trials ended

446 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 84 whose ending is known, 45% met their primary endpoint, 5% missed it and 50% stopped early.

  • Completed, result not reported17539%
  • Ongoing12227%
  • Status unknown6515%
  • Met its primary endpoint389%
  • Stopped: other or unclear174%
  • Stopped: enrollment or feasibility112%
  • Stopped: sponsor or business decision72%
  • Stopped: lack of efficacy61%
  • Missed its primary endpoint41%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 17; search them all in Canada trials
Aug 17, 2023A rollover study to provide continued access to mitapivat for participants who previously participated in an agios-sponsored mitapivat studyMitapivat (AG-348)Agios PharmaceuticalsOngoing
Nov 7, 2022An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent alpha- or beta-thalassemia or…Petadeferitrin (SP-420)PharmacosmosOngoing
Apr 6, 2022A multicenter study to evaluate the safety, tolerability, and efficacy of a single dose of autologous clustered regularly interspaced short palindromic repeats…EDIT-301 / Mozobil / FilgrastimEditas Medicine, Inc.Ongoing
Mar 10, 2022A phase 2 open-label study to evaluate safety and clinical activity of etavopivat in patients with thalassemia or sickle cell diseaseEtavopivat (FT-4202)Forma Therapeutics HoldingsClosed
Oct 28, 2021A phase 3 study to evaluate the safety and efficacy of a single dose of CTX001 in pediatric subjects with transfusion-dependent ¿-thalassemiaExagamglogene autotemcel (CTX001) / Busulfan / PlerixaforVertex PharmaceuticalsOngoing
Sep 8, 2021Novel transplant strategy for high-risk thalassemia patients a phase I/II trail of early fludarabine followed by abatacept and sirolimus immunosuppression…Abatacept/ SirolimusThe Hospital for Sick ChildrenOngoing
Apr 14, 2021A phase 3, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety ofmitapivat in subjects with…Mitapivat (AG-348)Agios PharmaceuticalsOngoing
Apr 13, 2021A phase 3, double-blind, randomized, placebo conbtrolled, multi-centre study evaluating the efficacy and safety of mitapivat in subjects with…Mitapivat (AG-348)Agios PharmaceuticalsOngoing
Nov 13, 2019A phase 2a, randomized, open-label study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of isis 702843 administered…Isis 702843 (IONIS-TMPRSS6-LRX)Ionis PharmaceuticalsClosed
Jul 15, 2019A phase 1b sequential open label dose ranging study of safety, pharmacokinetics, and preliminary activity of benserazide in subjects with beta thalassemia…BenserazidePhoenicia Biosciences Inc.Pending

FDA orphan designations

Approved first, then open designations, newest first; 15 of 30
Jul 1, 2026CasgevyTreatment of patients aged 2 years and older with transfusion-dependent beta-thalassemia (TDT)Vertex Pharmaceuticals Inc.Approved
Dec 23, 2025AqvesmeTreatment of anemia in adults with alpha- or beta-thalassemiaAgios Pharmaceuticals, Inc.Approved
Jan 16, 2024CasgevyTreatment of patients aged 12 years and older with transfusion-dependent beta-thalassemia (TDT)Vertex Pharmaceuticals Inc.Approved
Aug 17, 2022ZyntegloTreatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusionsGenetix Biotherapeutics Inc.Approved
Apr 30, 2021FerriproxTreatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes; and treatment…Chiesi USA, Inc.Approved
Apr 30, 2021FerriproxTreatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes; and treatment…Chiesi USA, Inc.Approved
May 19, 2020FerriproxFerriprox (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when…Chiesi USA, Inc.Approved
Nov 8, 2019ReblozylREBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC)…Celgene CorporationApproved
May 18, 2017Exjade; Jadenu SprinklesTreatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and…Novartis Pharmaceuticals CorporationApproved
Jan 23, 2013Exjade; Jadenu SprinklesTreatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and…Novartis Pharmaceuticals CorporationApproved
Oct 14, 2011FerriproxTreatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequateChiesi USA, Inc.Approved
Nov 4, 2025DesidustatTreatment of beta-thalassemiaZydus Lifesciences LimitedDesignated
Mar 21, 2025EtavopivatTreatment of thalassemiaNovo Nordisk Inc.Designated
Jul 11, 2024Genetically modified CD34+ hematopoietic stem cells using a…Treatment of beta-thalassemiaKanglin Biotechnology (Hangzhou) Co., Ltd.Designated
Dec 5, 2023Cutamesine dihydrochlorideTreatment of Alpha-thalassemia X-linked disability (ATRX) syndromeBioPharma Global, a division of Pace Life SciencesDesignated

Medicines authorised in the EU

Newest first
Feb 9, 2024CasgevyExagamglogene autotemcel · orphanVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Aug 28, 2006ExjadeDeferasiroxNovartis Europharm LimitedEMA ↗
Aug 25, 1999FerriproxDeferiproneChiesi Farmaceutici S.p.A.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.